Aims and scope
EJNMMI Radiopharmacy and Chemistry publishes new research in the field of development of new imaging and radionuclide based therapeutic agents for application in nuclear medicine and molecular imaging. The journal provides a platform for chemists, pharmacists and basic scientists to present their views and scientific work. In addition, the journal provides insight in novel concepts of imaging or radionuclide based therapeutic agent applications of relevance for the whole molecular imaging community. The journal reports original research articles, review papers, guidelines on application of imaging or radionuclide therapy agents, editorials, and letters to the editor. Research articles on novel radiochemistry, new radiopharmaceuticals including their first biological evaluation, molecular imaging agents including optical imaging, MRI, and hybrid probes, are the main focus of the journal. To translate imaging and radionuclide therapy agents to the clinic, legislative issues related to their production and safety can be presented as well in from of guidelines or position papers.
Why publish your article in EJNMMI Radiopharmacy and Chemistry?
EJNMMI Radiopharmacy and Chemistry's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.
Speed of publication
EJNMMI Radiopharmacy and Chemistry offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF; the article will then be available through EJNMMI Radiopharmacy and Chemistry and SpringerOpen.
Online publication in EJNMMI Radiopharmacy and Chemistry gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in EJNMMI Radiopharmacy and Chemistry are included in article alerts and regular email updates.
In addition, articles published in EJNMMI Radiopharmacy and Chemistry may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in EJNMMI Radiopharmacy and Chemistry.
Authors of articles published in EJNMMI Radiopharmacy and Chemistry retain the copyright of their articles and are free to reproduce and disseminate their work (for further details, see the copyright and license agreement).
For further information about the advantages of publishing in a journal from SpringerOpen, please click here.
All articles published by the EJNMMI Radiopharmacy and Chemistry are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
As authors of articles published in the EJNMMI Radiopharmacy and Chemistry you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the SpringerOpen copyright and license agreement.
For those of you who are US government employees or are prevented from being copyright holders for similar reasons, SpringerOpen can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. EJNMMI Radiopharmacy and Chemistry therefore levies an article-processing charge of £965.00/$1510.00/€1230.00 for each article accepted for publication, plus VAT or local taxes where applicable.
If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
SpringerOpen provides a free open access funding support service to help authors discover and apply for article processing charge funding. Visit our OA funding and policy support page to view our list of research funders and institutions that provide funding for APCs, and to learn more about our email support service.
The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by SpringerOpen on SpringerLink.
We are working closely with relevant indexing services including PubMed Central and Web of Science (Clarivate Analytics) to ensure that articles published inEJNMMI Radiopharmacy and Chemistry will be available in their databases when appropriate.
EJNMMI Radiopharmacy and Chemistry operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous Publication of research articles by EJNMMI Radiopharmacy and Chemistry is dependent primarily on their scientific validity and coherence as judged by our external expert editors and/or peer reviewers, who will also assess whether the writing is comprehensible and whether the work represents a useful contribution to the field.
Submitted manuscripts will generally be reviewed by two to three experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the manuscript is sufficiently clear for publication. Reviewers will also be asked to indicate how interesting and significant the research is. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board.
Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with the journals European Journal of Nuclear Medicine and Molecular Imaging, EJNMMI Research, EJNMMI Physics, and European Journal of Hybrid Imaging.
All manuscripts submitted to EJNMMI Radiopharmacy and Chemistry should adhere to SpringerOpen's editorial policies.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Citing articles in EJNMMI Radiopharmacy and Chemistry
Articles in EJNMMI Radiopharmacy and Chemistry should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Appl Inform [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Appl Inform 2009, 1:115.
refers to article 115 from Volume 1 of the journal.
Appeals and complaints
If you wish to appeal a rejection or make a complaint you should, in the first instance, contact the Editor who will provide details of the journal's complaints procedure.
- ISSN: 2365-421X
2017 Journal Metrics
34 days to first decision for reviewed manuscripts only
34 days to first decision for all manuscripts
59 days from submission to acceptance
22 days from acceptance to publication
25 Altmetric Mentions